
CLEAN PROFESSIONAL INFORMATION

SCHEDULING STATUS

Schedule 3

PROPRIETARY NAME (AND DOSAGE FORM)

ACULAR 0,5 % Ophthalmic Solution

COMPOSITION

ACULAR 0,5 % Ophthalmic Solution contains:

Ketorolac tromethamine 5 mg/ml

Preservatives:

Benzalkonium chloride 0,01 % m/v

Disodium edetate 0,1 % m/v

PHARMACOLOGICAL CLASSIFICATION

A 15.4 Ophthalmic preparations. Other.

PHARMACOLOGICAL ACTION

ACULAR 0,5 % (ketorolac tromethamine) is a non-steroidal anti-inflammatory agent demonstrating analgesic and anti-inflammatory activity. It is believed to inhibit the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins. ACULAR 0,5 % has been shown to reduce prostaglandin levels in the aqueous humour after topical ophthalmic administration.

Ketorolac tromethamine given systemically does not cause pupil constriction. Results from clinical studies indicate that ACULAR 0,5 % has no significant effect on intraocular pressure.

INDICATIONS

ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.

CONTRA-INDICATIONS

ACULAR 0,5 % is contra-indicated in patients hypersensitive to any component of the medicine.

The potential exists for cross-sensitivity to acetylsalicylic acid, phenyl acetic derivatives and other non-steroidal anti-inflammatory drugs.

ACULAR 0,5 % is contra-indicated in individuals who have previously exhibited sensitivities to the components.

Safety and effectiveness in children have not been established.

Safety of use in pregnant women has not been established (see PREGNANCY AND LACTATION).

ACULAR 0,5 % is not recommended for nursing mothers. Ketorolac tromethamine is secreted in human milk after systemic administration (see PREGNANCY AND LACTATION).

ACULAR 0,5 % should not be used while wearing soft contact lenses.

WARNINGS AND SPECIAL PRECAUTIONS

ACULAR 0,5 % contains the preservative benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of ACULAR 0,5 % and may be reinserted 15 minutes following administration.

As the possibility of adverse effects on the corneal permeability and danger of disruption of the corneal epithelium with prolonged or repeated usage of benzalkonium chloride preserved preparations cannot be excluded, regular ophthalmological examination is required.

Caution should be exercised in the use of benzalkonium chloride preserved topical medication over an extended period in patients with extensive ocular surface disease.

There have been post-marketing reports of bronchospasm or exacerbation of asthma in patients, who have either a known hypersensitivity to aspirin/NSAIDs or a past medical history of asthma associated with the use of ACULAR 0,5 %, which may be contributory.

With ACULAR 0,5 %, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphaemas) in conjunction with surgery.

It is recommended that ACULAR 0,5 % be used with caution in patients with known bleeding tendencies or who are receiving other medication which may prolong bleeding time and in patients with known history of peptic ulceration.

In common with other anti-inflammatory medicines, ACULAR 0,5 % may mask the usual signs of infection.

General: ACULAR 0,5 % may slow or delay healing.

Use of ACULAR 0,5 % may result in keratitis. In such patients, continued use of ACULAR 0,5 % may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may lead to blindness. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of ACULAR 0,5 % and should be closely monitored for corneal health.

ACULAR 0,5 % should be used with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g. dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time, as they may be at increased risk for corneal adverse events which may become sight threatening.

Post-marketing experience with topical NSAIDs, such as ACULAR 0,5 %, also suggest that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

Effects on ability to drive and use machines

Upon instillation, patients may experience transient blurred vision which may impair the ability to drive or use machinery. If affected, patients should not drive or use machinery until their vision has cleared.

INTERACTIONS

ACULAR 0,5 % has been safely administered with systemic and ophthalmic medications such

as antibiotics, sedatives, beta blockers, carbonic anhydrase inhibitors, miotics, mydriatics, cycloplegics and corticosteroids.

PREGNANCY AND LACTATION

Pregnancy

Safety and efficacy in human pregnancy have not been established.

Lactation

Ketorolac tromethamine, the active ingredient in ACULAR 0,5 %, is secreted in human milk after systemic administration. Therefore, mothers using ACULAR 0,5 % should not be breastfeeding their infants.

DOSAGE AND DIRECTIONS FOR USE

One drop instilled into the eye three times daily starting 24 hours before surgery and continuing post-operatively.

SIDE EFFECTS

The most frequent side effects reported with the use of ACULAR 0,5 % are stinging and burning on instillation.

Blurring and/or diminished vision have been reported with the use of ACULAR 0,5 %.

The use of ACULAR 0,5% while wearing soft (hydrophilic) contact lenses is not recommended.

The events below are classified according to their incidence in clinical trials. The frequency of adverse reactions is given as follows: Very common ($\geq 1/10$); Common ($\geq 1/100$, $< 1/10$);

Uncommon ($\geq 1/1\ 000$, $< 1/100$); Rare ($\geq 1/10\ 000$, $< 1/1\ 000$); Very rare ($< 1/10\ 000$); not known (cannot be estimated from the available data).

Eye disorders

Common: Iritis, keratic precipitates, hem retinal, cystoid macular oedema, eye burning, eye pruritus, eye trauma, increased intraocular pressure

Immune system disorders

Common: Hypersensitivity

Nervous system disorders

Common: Headache

None of the typical adverse reactions reported with the systemic non-steroidal anti-inflammatory agents have been observed at the doses used in topical ophthalmic therapy.

Post-marketing experience

The following adverse reactions have been identified during post-marketing use of ACULAR 0,5 %. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to ACULAR 0,5 %.

Eye disorders: Eye irritation, eyelid oedema, eye oedema, ocular hyperaemia, conjunctival hyperaemia, eye swelling, eye pain, eye pruritus and ulcerative keratitis

There have been post-marketing reports of bronchospasm or exacerbation of asthma in

patients, who have either a known hypersensitivity to aspirin/NSAIDS or a past medical history of asthma associated with the use of ACULAR 0,5 %, which may be contributory.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT

In the event of topical overdose, wash the eye with water.

If accidentally ingested, drink fluids to dilute

Treatment is symptomatic and supportive.

IDENTIFICATION

ACULAR 0,5 % is a clear, colourless to slight yellow sterile ophthalmic solution.

PRESENTATION

ACULAR 0,5 % is supplied in sterile dropper bottles containing 5 ml solution.

STORAGE INSTRUCTIONS

Store below 25°C. Do not use more than 30 days after opening.

KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER

29/15.4/0265

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION

AbbVie (Pty) Ltd

Building 7, Waterfall Corporate Campus

74 Waterfall Drive

Waterfall City

Midrand, 1685

South Africa

DATE OF PUBLICATION OF THE PROFESSIONAL INFORMATION

Date of registration: 27 November 1995

Date of most recently revised Professional Information as approved by the Authority: 21 April
2023